Loading...
XHKG
1061
Market cap290mUSD
Dec 05, Last price  
3.99HKD
1D
-2.21%
1Q
-24.43%
Jan 2017
19.82%
IPO
333.70%
Name

Essex Bio-Technology Ltd

Chart & Performance

D1W1MN
XHKG:1061 chart
P/E
7.36
P/S
1.35
EPS
0.54
Div Yield, %
4.14%
Shrs. gr., 5y
-0.73%
Rev. gr., 5y
5.47%
Revenues
1.67b
-2.15%
49,197,29182,789,684152,674,582214,070,523116,688,187146,281,574212,716,340267,255,167347,046,987518,299,695654,010,499775,662,998899,589,7291,176,457,9311,279,478,212978,111,1261,637,659,4311,317,710,6161,706,556,1411,669,816,770
Net income
307m
+11.61%
15,547,7533,763,27711,001,92621,826,71011,550,88926,584,37233,202,62838,995,13654,896,69675,273,091104,895,190136,284,381167,298,653231,091,674302,502,420218,925,555345,968,083225,411,310275,259,617307,221,818
CFO
368m
+8.63%
-2,224,8804,403,899-5,786,1943,746,69746,631,16328,123,45223,380,40935,788,51765,119,10334,922,49168,640,46585,278,686193,720,031200,872,681232,858,075299,238,146409,161,400382,785,659339,205,269368,470,081
Dividend
Sep 09, 20240.06 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.
IPO date
Jun 27, 2001
Employees
1,462
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT